Overview

A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study will determine if MK-3614, given as single doses, is safe and well tolerated in healthy males and male participants with mild to moderate hypertension.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.